{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:09:13Z","timestamp":1779923353462,"version":"3.53.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T00:00:00Z","timestamp":1428537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.jhep.2015.03.029","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T21:26:14Z","timestamp":1428269174000},"page":"364-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Ombitasvir\/paritaprevir\/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine"],"prefix":"10.1016","volume":"63","author":[{"given":"Jacob","family":"Lalezari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Greg","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Varunok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Galen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Rustgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Felizarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshanth R.","family":"Polepally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2015.03.029_b0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrgastro.2013.179","article-title":"HCV transmission in industrialized countries and resource-constrained areas","volume":"11","author":"Thursz","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.03.029_b0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2015.03.029_b0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2105\/AJPH.91.1.23","article-title":"Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City","volume":"91","author":"Diaz","year":"2001","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jhep.2015.03.029_b0020","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005792-199507000-00005","article-title":"Correlates of hepatitis C virus infections among injection drug users","volume":"74","author":"Thomas","year":"1995","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2015.03.029_b0025","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2893.2009.01080.x","article-title":"Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents","volume":"16","author":"Grebely","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.03.029_b0030","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"Mehta","year":"2008","journal-title":"J Community Health"},{"key":"10.1016\/j.jhep.2015.03.029_b0035","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1086\/427445","article-title":"Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users","volume":"40","author":"Strathdee","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.03.029_b0040","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.03.029_b0045","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.03.029_b0050","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.03.029_b0055","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.03.029_b0060","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/cit306","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis","volume":"57","author":"Aspinall","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.03.029_b0065","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/cid\/cis1007","article-title":"Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis","volume":"56","author":"Dimova","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.03.029_b0070","doi-asserted-by":"crossref","unstructured":"Menon RM, Klein CE, Lawal AA, Chiu Y-L, Awni WM, Podsadecki TJ, et al. Pharmacokinetics and tolerability of the HCV protease inhibitor ABT-450 following single ascending doses in healthy adult volunteers with and without ritonavir. HepDART. Kohala Coast, HI; 2009.","DOI":"10.1016\/S0168-8278(09)60958-2"},{"key":"10.1016\/j.jhep.2015.03.029_b0075","first-page":"S470","article-title":"1187 ABT-450\/ritonavir (ABT-450\/r) combined with pegylated interferon alpha-2a\/ribavirin after 3-day monotherapy in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12-week sustained virologic response (SVR12) and safety results","volume":"56","author":"Lawitz","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.03.029_b0080","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S0168-8278(12)61198-2","article-title":"1186 Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: First study in HCV genotype-1 (GT1)-infected treatment-naive subjects","volume":"56","author":"Lawitz","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.03.029_b0085","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.1016\/S0168-8278(12)61218-5","article-title":"1206 ABT-072 or ABT-333 combined with pegylated interferon\/ribavirin after 3-day monotherapy in HCV genotype 1 (GT1)-infected treatment-naive subjects: 12-week sustained virologic response (SVR12) and safety results","volume":"56","author":"Poordad","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.03.029_b0090","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.03.029_b0095","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1306227","article-title":"Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.03.029_b0100","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.03.029_b0105","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/jvh.12008","article-title":"Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers","volume":"19","author":"Bruggmann","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.03.029_b0110","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/jvh.12183","article-title":"Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study","volume":"21","author":"Treloar","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.03.029_b0115","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1089\/apc.2010.0142","article-title":"Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration","volume":"24","author":"Swan","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.jhep.2015.03.029_b0120","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","article-title":"A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus","volume":"8","author":"Singal","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2015.03.029_b0125","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/cid\/cit377","article-title":"Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements","volume":"57","author":"Grebely","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2015.03.029_b0130","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jhep.2010.08.029","article-title":"Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility","volume":"54","author":"Martin","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.03.029_b0135","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1111\/j.1365-2893.2010.01370.x","article-title":"Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia","volume":"18","author":"Grebely","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2015.03.029_b0140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drugalcdep.2004.07.002","article-title":"The impact of injecting drug use status on hepatitis C-related referral and treatment","volume":"77","author":"Stoove","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jhep.2015.03.029_b0145","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/liv.12080","article-title":"How to optimize HCV therapy in genotype 1 patients: management of side-effects","volume":"33","author":"Chopra","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2015.03.029_b0150","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jhep.2010.08.040","article-title":"Potency, safety, and pharmacokinetics of the NS3\/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection","volume":"54","author":"Manns","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.03.029_b0155","unstructured":"Menon RM, Badri P, Das U, Wang T, Polepally A, Khatri A, et al. Drug-Drug Interactions with Direct Acting Antiviral Combination Therapy of ABT-450\/r, Ombitasvir and Dasabuvir. 54th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC); 2014 September 5\u20139, 2014; Washington D.C.; 2014. A-007."},{"key":"10.1016\/j.jhep.2015.03.029_b0160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2015.01.026","article-title":"Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir\/ritonavir, ombitasvir and dasabuvir","volume":"63","author":"Menon","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2015.03.029_b0165","unstructured":"COPEGUS (ribavirin) [package insert]. Genentech\/Roche: South San Francisco, CA; 2013."},{"key":"10.1016\/j.jhep.2015.03.029_b0170","unstructured":"REBETOL (ribavirin) [package insert]. Merck & Co.: Whitehouse Station, NJ, USA; 2013."},{"key":"10.1016\/j.jhep.2015.03.029_b0175","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-Ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.03.029_b0180","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"Andreone","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2015.03.029_b0185","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2015.03.029_b0195","series-title":"SVR12 of 99% achieved with a ribavirin-free regimen of ABT-450\/r\/ombitasvir and dasabuvir in HCV genotype 1b-infected patients","author":"Maieron","year":"2014"},{"key":"10.1016\/j.jhep.2015.03.029_b0190","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1093\/cid\/cit302","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"57","author":"Robaeys","year":"2013","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815002378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827815002378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T20:08:10Z","timestamp":1566504490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827815002378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0168827815002378"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2015.03.029","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725419626.793505864","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ombitasvir\/paritaprevir\/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2015.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}